Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang, Michael Quigley(Scripps Health), Megan Raymond, Ignacio Melero(University of Oxford), Michael Ong(University of California, Los Angeles), Ed Hilt, Dominic Kabbabe, Alan J. Korman(Bristol-Myers Squibb (Germany)), Kent Thudium, Paula M. Fracasso(University of Virginia), Shih-Min A. Huang(Novartis (Switzerland)), Christina Milburn, Gennaro Dito, Anthony J. Olszanski(Fox Chase Cancer Center), Richard D. Carvajal(Northwell Health), Anna Spreafico(University Health Network), Yongliang Sun, Xiao Shao, Chan Gao(Zhejiang Chinese Medical University), Irene Pak, Martin Gutierrez(Hackensack University Medical Center), Feng Yan, Praveen Aanur(Moderna Therapeutics (United States))
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Cytokines in clinical cancer immunotherapy
|British Journal of Cancer|2018|1.2k